Nordic Nanovector (Group)

https://www.nordicnanovector.com

Nordic Nanovector is a biotech company focusing on the development and commercialization of novel targeted therapeutics in haematology and oncology. The Company’s lead clinical-stage product opportunity is Betalutin™, the first in a new class of Antibody-Radio-Conjugates (ARCs), designed to improve upon and complement current options for the treatment of Non-Hodgkin’s Lymphoma (NHL). NHL is an indication with substantial unmet medical need and orphan drug opportunities, representing a growing market worth over $12 billion by 2018. Betalutin™ comprises a tumor-seeking anti-CD37 antibody conjugated to low intensity radionuclide (Lutetium 177). It has shown promising efficacy in Phase 1 studies in a difficult-to-treat NHL patient population and as well as a very favourable tolerability. Betalutin™ is fast advancing through clinical development and with first approval anticipated in 2018. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialization of Betalutin™ in core markets, while exploring potential distribution agreements in selected geographies. The Company is committed to developing its ARC pipeline to treat a number of select cancer indications. *

	Start	2009-01-01 established
	Today	Nordic Nanovector ASA (OSE: NANOV)
	Predecessor	Nordic Nanovector AS
	Industry	Betalutin®
	Industry 2	cancer immunotherapy (immuno-oncology, I-O)
	Person	Skullerud, Erik (Nordic Nanovector 202109– CEO before Element Consulting GmbH + Amgen + Bayer)
	Person 2	Kvåle, Tone (Nordic Nanovector 201409 CFO)

	Region	Oslo
	Country	Norway
	Street	168 B Kjelsåsveien
	City	0884 Oslo
	Tel	+47-22-183301
		Address record changed: 2020-12-02

Basic data	Employees	n. a.
	Currency	NOK
	Annual sales	437,000 (revenues, consolidated (2015) 2015-12-31)
	Profit	-137,075,000 (2015-12-31)
	Cash	743,367,000 (2015-12-31)

		* Document for »About Section«:

		Record changed: 2024-02-12